Neurocrine Biosciences Inc NBIX
We take great care to ensure that the data presented and summarized in this overview for NEUROCRINE BIOSCIENCES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NBIX
View all-
Black Rock Inc. New York, NY13.8MShares$1.96 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.93MShares$1.41 Billion0.03% of portfolio
-
State Street Corp Boston, MA3.99MShares$568 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.3MShares$327 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.25MShares$320 Million0.49% of portfolio
-
Morgan Stanley New York, NY2.07MShares$294 Million0.02% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.06MShares$293 Million4.44% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.82MShares$259 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA1.71MShares$244 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X01.38MShares$196 Million0.11% of portfolio
Latest Institutional Activity in NBIX
Top Purchases
Top Sells
About NBIX
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL ? Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Insider Transactions at NBIX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 15
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-32.24%
|
$2,100,000
$140.24 P/Share
|
May 15
2024
|
Matt Abernethy Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+24.38%
|
$1,095,000
$73.6 P/Share
|
May 14
2024
|
Gary A Lyons Director |
SELL
Open market or private sale
|
Direct |
12,500
-9.66%
|
$1,687,500
$135.63 P/Share
|
May 14
2024
|
Gary A Lyons Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+8.81%
|
$525,000
$42.76 P/Share
|
May 14
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-32.24%
|
$2,025,000
$135.66 P/Share
|
May 14
2024
|
Matt Abernethy Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+24.38%
|
$1,095,000
$73.6 P/Share
|
May 06
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
273
-3.51%
|
$38,220
$140.55 P/Share
|
May 06
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
273
+3.39%
|
$21,567
$79.02 P/Share
|
Apr 15
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
19,818
-19.32%
|
$2,635,794
$133.36 P/Share
|
Apr 15
2024
|
Eric Benevich Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,818
+16.09%
|
$1,605,258
$81.27 P/Share
|
Apr 01
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
272
-3.5%
|
$37,264
$137.3 P/Share
|
Apr 01
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
272
+3.38%
|
$21,488
$79.02 P/Share
|
Mar 21
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
5,000
-39.98%
|
$725,000
$145.06 P/Share
|
Mar 21
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+28.56%
|
$515,000
$103.52 P/Share
|
Mar 14
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
75,000
-37.44%
|
$10,425,000
$139.38 P/Share
|
Mar 14
2024
|
Eric Benevich Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+24.63%
|
$6,000,000
$80.04 P/Share
|
Mar 14
2024
|
George J Morrow Director |
SELL
Open market or private sale
|
Direct |
40,000
-100.0%
|
$5,560,000
$139.42 P/Share
|
Mar 14
2024
|
George J Morrow Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+50.0%
|
$1,560,000
$39.79 P/Share
|
Mar 13
2024
|
Richard F Pops Director |
SELL
Open market or private sale
|
Direct |
23,200
-44.01%
|
$3,248,000
$140.33 P/Share
|
Mar 13
2024
|
Richard F Pops Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,200
+30.56%
|
$974,400
$42.76 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 755K shares |
---|
Open market or private sale | 859K shares |
---|---|
Bona fide gift | 2.94K shares |